Team Pontus Nauclér
Misuse of antibiotics accelerates development and spread of drug-resistance. Our group's research focus is: Targeted antibiotic therapy of patients with severe infections to improve clinical impact and reduce resistance.
Reducing antibiotic resistance
We live in a world of increasingly scarce resources when it comes to antibiotics. The World Health Organization estimates 700 000 deaths from antibiotic resistance yearly that could rise to 10 million per year by 2050. Misuse of antibiotics accelerates development and spread of drug-resistance. Improved strategies of antibiotic treatment in patients with severe infections are urgently needed to improve survival and to reduce unnecessary usage of antibiotics that leads to resistance development.
Research focus: Targeted antibiotic therapy of patients with severe infections to improve clinical impact and reduce resistance.
We combine large databases of clinical and microbiological data to study 1) the impact of antibiotic treatment and vaccine strategies, 2) screening algorithms to guide antibiotic treatment, and 3) genetic properties of bacteria that can be exploited for future therapeutic interventions. We primarily focus on healthcare-associated infections, pneumonia and gram-negative infections. The studies are performed within test-beds of electronic health records, national register-based research databases of infections, and clinical studies performed in collaboration with national and international researchers. Currently we lead a Vinnova-financed triple-helix project (academia, public partners, and industry) to develop novel big-data driven techniques to curb healthcare-associated infections.
- Pontus Nauclér, MD, PhD, Assosiate Professor, Team Leader
- Suzanne Desirée Ruhe Van Der Werff, Postdoctoral researcher
- Mohammad Razavi, Postdoctoral researcher
- Nicholas Baltzer, Postdoctoral researcher
- John Karlsson Valik, MD Phd student
- Pontus Hedberg, Phd student
- Nishi Dave, Research Assistant
- Katie Isitt, PhD student
- Anders Ternhag, MD Associate Professor, Affiliated
- Andreas Berge, MD, PhD, Senior Physician, Affiliated
- Åke Örtqvist, MD Associate Professor, Affiliated
- Martin Glimåker, MD, PhD, Senior Physician, Affiliated
- Per Englund Affiliated
- Fredrik Holmberg, Affiliated
- Hideyuki Tanushi, Affiliated
Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
Rhedin S, Galanis I, Granath F, Ternhag A, Hedlund J, Spindler C, et al
Clin. Microbiol. Infect. 2017 Apr;23(4):247-252
Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study.
Ny S, Löfmark S, Börjesson S, Englund S, Ringman M, Bergström J, et al
J. Antimicrob. Chemother. 2017 02;72(2):582-588
Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, et al
Eur. Respir. J. 2016 Apr;47(4):1208-18
Betamethasone and dexamethasone in adult community-acquired bacterial meningitis: a quality registry study from 1995 to 2014.
Glimåker M, Brink M, Naucler P, Sjölin J
Clin. Microbiol. Infect. 2016 Sep;22(9):814.e1-814.e7
Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study.
Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Öhrmalm L, Tolfvenstam T, et al
Thorax 2015 Sep;70(9):847-53
Prevalence of community-acquired bacteraemia in Guinea-Bissau: an observational study.
Isendahl J, Manjuba C, Rodrigues A, Xu W, Henriques-Normark B, Giske CG, et al
BMC Infect. Dis. 2014 Dec;14():3859
Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.
Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B
Thorax 2013 Jun;68(6):571-9